Kinikli Gülay, Ateş Aşkin, Turgay Murat, Aydoğan Nergis, Tokgöz Güner
Department of Clinical Immunology and Rheumatology, Ankara University Medical School, Turkey.
Allergy Asthma Proc. 2006 Mar-Apr;27(2):145-7.
There have been conflicting reports on the relationship between Fas/Fas ligand-mediated apoptosis and allergic response. Specific immunotherapy (SIT) is widely used for treatment of allergic diseases. It has long been apparent that SIT results in a reduction in antigen-specific lymphoproliferation, but it is unclear by what mechanism T-cell responses are inhibited by SIT in vivo. In this study, we examined serum-soluble Fas (sFas) levels in patients with allergic rhinitis and healthy subjects. We also examined the effect of SIT on sFas level. Seventy-two patients with allergic rhinitis and 20 healthy subjects were included in this study. Twenty-eight patients were newly diagnosed and 44 patients were treated with SIT for a 5-year or 7-year duration. Serum sFas levels were measured by a sandwich enzyme-linked immunoassay. Mean serum sFas level was 7931 +/- 2861 pg/mL in newly diagnosed patients with allergic rhinitis during the pollen season, 8426 +/- 2846 pg/mL in patients with allergic rhinitis treated by SIT for a 5-year duration, 8490 +/- 2256 pg/mL in patients with allergic rhinitis treated by SIT for a 7-year duration, and 7493 +/- 3450 pg/mL in healthy subjects. Serum sFas level was not found to be significantly different among the study groups (p > 0.05). These findings suggest that there is no relation between sFas level and the etiopathogenesis of allergic inflammation in patients with allergic rhinitis and mechanism of action of SIT.
关于Fas/Fas配体介导的细胞凋亡与过敏反应之间的关系，一直存在相互矛盾的报道。特异性免疫疗法（SIT）被广泛用于治疗过敏性疾病。长期以来，很明显SIT会导致抗原特异性淋巴细胞增殖减少，但目前尚不清楚SIT在体内抑制T细胞反应的机制是什么。在本研究中，我们检测了过敏性鼻炎患者和健康受试者血清中可溶性Fas（sFas）水平。我们还研究了SIT对sFas水平的影响。本研究纳入了72例过敏性鼻炎患者和20名健康受试者。其中28例为新诊断患者，44例接受了为期5年或7年的SIT治疗。采用夹心酶联免疫吸附测定法检测血清sFas水平。在花粉季节，新诊断的过敏性鼻炎患者血清sFas平均水平为7931±2861 pg/mL，接受5年SIT治疗的过敏性鼻炎患者为8426±2846 pg/mL，接受7年SIT治疗的过敏性鼻炎患者为8490±2256 pg/mL，健康受试者为7493±3450 pg/mL。各研究组之间血清sFas水平差异无统计学意义（p>0.05）。这些结果表明，sFas水平与过敏性鼻炎患者过敏性炎症的发病机制及SIT的作用机制无关。
